Grant of options

14 June 2016

MaxCyte, Inc.

("MaxCyte" or the "Company")

Grant of Options

Maryland, USA - MaxCyte (LSE: MXCT), an established and revenue generating US-based developer and supplier of cell engineering technology to biotechnology and pharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology, announces that it granted, effective of today, options over a total of 709,900 common stock of $0.01 per share in the Company ("Common Stock") to certain directors and applicable employees of the Company ("Option Grants"). Details of the Option Grants are given below:

Option Grants vest ratably on a monthly basis following grant (i) for Doug Doerfler, Ron Holtz and Madhusudan Peshwa, over 48 months, (ii) for Will Brooke and John Johnston, over 36 months, and (iii) for Stan Erck, Art Mandell and Stark Thompson, over 12 months. The Option Grants have an exercise period of 10 years from date of grant, at which time they will expire.

Certain other employees and one consultant have received Option Grants over a total of 392,300 Common Stock, effective of today, at an exercise price of 81.50p per option, which have an exercise period of 10 years.

- Ends -

For further information please contact:

About MaxCyte

MaxCyte is an established and revenue generating US-based developer and supplier of cell engineering technology to biotechnology and pharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology. The Company's patented flow electroporation technology enables its products to deliver fast, reliable and scalable cell engineering to drive the research and clinical development of a new generation of cell-based medicines.

MaxCyte's high performance platform allows transfection with any molecule or multiple molecules and is compatible with nearly all cell types, including hard-to-transfect human primary cells. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large scale, commercial and clinical grade cell engineering in a non-viral system and with low toxicity concerns. The Company's cell engineering technology platform is CE-marked and FDA-accredited, providing MaxCyte's customers with an established regulatory path.

MaxCyte is developing CARMA, its proprietary platform in immuno-oncology, to deliver a validated non-viral approach to CAR therapies in a number of cancer indications, including solid tumors.

For more information visit http://www.maxcyte.com/